EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 is a small molecule inhibitor that selectively targets the DOT1L histone methyltransferase with an IC₅₀ of 0.8 nM, exhibiting over 37,000-fold selectivity against other methyltransferases (APExBIO). It acts by occupying the S-adenosyl methionine (SAM) binding pocket of DOT1L, altering the enzyme’s conformation and inhibiting H3K79 methylation (Daigle 2013, DOI). In preclinical models, EPZ5676 induced complete regression of MV4-11 xenograft tumors without significant toxicity. The compound is optimized for in vitro and in vivo use in leukemia models, with robust solubility in DMSO and ethanol but not water. Its use is foundational for studies dissecting epigenetic regulation in MLL-rearranged leukemia (Anbazhagan et al., 2024).

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is the sole histone methyltransferase responsible for methylation of lysine 79 on histone H3 (H3K79). Aberrant H3K79 methylation is a hallmark of MLL (Mixed-Lineage Leukemia) gene rearrangements driving acute leukemia pathogenesis (Daigle 2013). In MLL-rearranged leukemias, fusion proteins recruit DOT1L to aberrant chromatin sites, leading to sustained H3K79 methylation and transcriptional activation of oncogenic targets such as HOXA9 and MEIS1. Chemical inhibition of DOT1L reverses these modifications, suppressing proliferation and viability of leukemia cells with MLL translocations (APExBIO).

Recent research in epigenetic regulation, including studies on class IIa HDACs and prostaglandin signaling, highlights the importance of chromatin-modifying enzymes as therapeutic targets in cancer and inflammatory disease (Anbazhagan et al., 2024). While HDAC inhibitors regulate acetylation, DOT1L inhibitors like EPZ5676 target methylation, providing orthogonal approaches to epigenetic intervention.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a SAM-competitive inhibitor. It binds in the methyl donor site of DOT1L, inducing conformational changes that open a hydrophobic pocket not accessible to SAM’s natural ligands (APExBIO). This selectively blocks DOT1L’s methyltransferase activity, preventing H3K79 methylation. The compound shows an IC₅₀ of 0.8 nM and Ki of 80 pM in biochemical assays.

EPZ5676’s selectivity profile demonstrates >37,000-fold selectivity over other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. This high specificity minimizes off-target effects and underscores its utility in dissecting DOT1L-dependent pathways. In MLL-rearranged leukemia cells, DOT1L inhibition leads to a decrease in H3K79me2 levels and downregulation of MLL-fusion target genes, inducing apoptotic cell death (Daigle 2013).

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L with an IC₅₀ of 0.8 nM in biochemical enzyme assays (APExBIO, product page).
• Demonstrates >37,000-fold selectivity for DOT1L over other methyltransferases (Daigle 2013, DOI).
• Reduces H3K79 methylation and MLL-fusion gene expression in MV4-11 leukemia cells, with an antiproliferative IC₅₀ of 3.5 nM after 4–7 days (APExBIO, product page).
• In nude rat MV4-11 xenograft models, intravenous administration (35–70 mg/kg/day for 21 days) caused complete tumor regression with no significant toxicity (Daigle 2013, DOI).
• Long-term storage of stock solutions in DMSO at ≤−20°C preserves compound stability (APExBIO, product page).
• Related studies confirm the critical role of chromatin-modifying enzymes in mucosal repair, barrier function, and inflammation, placing DOT1L inhibition within a broader epigenetic regulatory landscape (Anbazhagan et al., 2024, DOI).

For a broader mechanistic and translational context, see this article, which details how EPZ5676 enables strategic dissection of H3K79 methylation; the present article extends this by providing updated benchmarks and workflow parameters relevant for assay design.

Applications, Limits & Misconceptions

EPZ5676 is primarily used in biochemical DOT1L inhibition assays, cell proliferation studies, and in vivo leukemia models. Its high specificity makes it ideal for mechanistic studies in MLL-rearranged leukemia and for validating DOT1L as a therapeutic target.

Common Pitfalls or Misconceptions

• Not a broad-spectrum methyltransferase inhibitor: EPZ5676 is ineffective against non-DOT1L methyltransferases due to its highly selective binding mode.
• Limited water solubility: The compound is insoluble in water and must be prepared in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasonic assistance).
• No direct activity on HDACs: Unlike HDAC inhibitors (see Anbazhagan et al., 2024), EPZ5676 does not modulate histone acetylation.
• Not a pan-cancer agent: Demonstrated cytotoxicity is specific to MLL-rearranged leukemia models, with limited evidence in other cancers.
• Requires prolonged exposure for cell-based effects: Antiproliferative activity in MV4-11 cells requires 4–7 days of continuous treatment.

For a detailed breakdown of experimental strategies and limitations, this review provides a comparative analysis of epigenetic inhibitors; the present article clarifies the selectivity and workflow parameters unique to EPZ5676.

Workflow Integration & Parameters

EPZ5676 is supplied as a solid (molecular weight 562.71). For in vitro assays, dissolve in DMSO at concentrations up to 28.15 mg/mL, or in ethanol up to 50.3 mg/mL with ultrasonic assistance. Stock solutions should be stored at −20°C or below; avoid repeated freeze-thaw cycles. For in vivo studies, dosing in rats at 35–70 mg/kg/day intravenously for 21 days has achieved complete regression of MV4-11 xenografts without significant toxicity (Daigle 2013).

Recommended uses include biochemical enzyme inhibition assays, cell proliferation and apoptosis assays in MLL-rearranged acute leukemia cell lines, and in vivo efficacy testing in xenograft models. For up-to-date workflow guidance and advanced integration with precision epigenetic research, see the Precision Epigenetic Intervention article; this article updates those recommendations with current product stability and selectivity data.

Conclusion & Outlook

DOT1L inhibitor EPZ5676 (A4166) from APExBIO is a gold-standard tool for dissecting epigenetic mechanisms in MLL-rearranged leukemia. Its high potency, selectivity, and robust performance in preclinical assays inform both basic biology and translational research. As studies in chromatin-modifying enzymes expand, compounds like EPZ5676 will remain central to precision oncology and epigenetic drug discovery (Anbazhagan et al., 2024).

For ordering and technical details, visit the DOT1L inhibitor EPZ-5676 product page.